FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| OMB APPROVAL | | | | |
|--------------------------|-----------|--|--|--|
| OMB Number: | 3235-0104 | | | |
| Estimated average burden | | | | |
| nours per response | | | | |

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Responses) | | | | | | | | |
|---|---------------------|---|----------------------------|--|---|---|---|--|
| Name and Address of Reporting Person * Solomon Jonathan Eitan | Statem | 2. Date of Event Requiring Statement (Month/Day/Year) 10/28/2019 | | 3. Issuer Name and Ticker or Trading Symbol BiomX Inc. [PHGE] | | | | |
| (Last) (First) (Middle) C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2 | 1 | | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X Officer (give title below) Chief Executive Officer | | / | 5. If Amendment, Date Original Filed(Month/Day/Year) | |
| (Street) NESS ZIONA, L3 7414002 | | | | | | Applicable L _X_ Form file | 6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting PersonForm filed by More than One Reporting Person | |
| (City) (State) (Zip) | | Table I - Non-Derivative Securities Beneficially Owned | | | | | wned | |
| 1.Title of Security (Instr. 4) | · | Beneficially Owned F (Instr. 4) | | | * | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | |
| Reminder: Report on a separate line for each cla | ond to the | collection of | information | contained in th | nis form are not | required to res | SEC 1473 (7-02 | |
| | | • | | | ants, options, conv | ertible securities | s) | |
| 1. Title of Derivative Security (Instr. 4) 2. 1 Exp | | Date Exercisable and piration Date Securities Security (Instr. 4) | | | 4. Conversion e or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | |
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Security | Direct (D) or Indirect (I) (Instr. 5) | | |
| Common Stock Options - Right to Buy | (1) | 01/07/2027 | Common Stock Options | 167,434 | \$ 0.54 | D | | |
| Common Stock Options - Right to Buy | <u>(2)</u> | 03/26/2027 | Common Stock Options | 182,133 | \$ 1.69 | D | | |
| Common Stock Options - Right to Buy | (3) | 05/22/2028 | Common Stock Options | 201,718 | \$ 1.97 | D | | |
| Common Stock Options - Right to Buy | <u>(4)</u> | 03/29/2029 | Common Stock Options | 284,701 | \$ 2.03 | D | | |

Reporting Owners

| | Relationships | | | |
|---|---------------|--------------|-------------------------|-------|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other |
| Solomon Jonathan Eitan C/O BIOMX LTD. 7 PINHAS SAPIR ST., FLOOR 2 NESS ZIONA, L3 7414002 | X | | Chief Executive Officer | |

Signatures

| /s/ Jonathan Solomon | 11/05/2019 |
|---------------------------------|------------|
| **Signature of Reporting Person | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 20% of these options vested upon Mr. Solomon's appointment as Chief Executive Officer of BiomX Ltd., a wholly-owned subsidiary of the Issuer, in February 2017. Of the (1) remaining 80%, 25% vested on February 1, 2017, with the remaining options vesting in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 52,316 shares of common stock were unvested.
- (2) 25% of these options vested on March 26, 2018. Thereafter, the remaining options shall vest in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 68,301 shares of common stock were unvested.
- (3) 25% of these options vested on May 22, 2019. Thereafter, the remaining options shall vest in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 138,682 shares of common stock were unvested.
- (4) 25% of these options shall vest on March 29, 2020. Thereafter, the remaining options shall vest in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 284,701 shares of common stock were unvested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.